The latest induced, embryonic, and other pluripotent stem cell news.
Syntax is bringing its Cellgorithm cell-therapy discovery platform to the table, while Mayo Clinic will provide expertise in pancreatic biology and functional testing for preclinical diabetes.
JAX will use the funding to study how a genetic variant affects the disease and potentially standardize and characterize human cell models for broader research.
Published in the Journal of Nanobiotechnology, the iPSC-derived therapy delivers BDNF mRNA to injured spinal tissue, improving motor recovery in preclinical studies.
Building on work at the University of Wisconsin-Madison, the Australian biotech company expects to release data from its Phase 3 iPSC-derived MSC KOA & Phase 2 Graft-vs-Host-Disease trials in the coming months.
The company is working on iPSC-derived, AAV, and small molecule therapies for neurodegenerative, orthopedic, and blood-based disorders, with the help of OpenAI's models which seem to be accelerating life science research.
The site will also serve as the company's new headquarters, expanding its services in iPSC-based drug discovery, regenerative medicine, and cell therapy work.
The partnership hopes to speed up the scalable development of SC451 for type 1 diabetes by standardizing treatment protocols, improving clinical delivery and post-care, and preparing the therapy for broader use across...
Cartherics is developing multiple immune cell therapies for women's health, including its lead candidate, CTH-401, a CAR-NK therapy targeting ovarian cancer.
Cellular Intelligence will use its AI platform to speed the clinical development and scalable manufacturing of a Phase 1/2 stem cell-derived Parkinson’s therapy acquired from Novo Nordisk, which also took an equity...
Trailhead Biosystems has launched a functionally validated, highly pure iPSC-derived endothelial cell product designed to give researchers a scalable, reproducible human vascular model for angiogenesis, inflammation, drug screening and toxicity studies.
